Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. - Wikidata - wikimedia - TriplyDB

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

http://www.wikidata.org/entity/Q37924869

about

Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment Emerging therapy for adrenocortical carcinoma.Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline Effects of mitotane treatment on human steroid metabolism: implications for patient management.Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.Mitotane-induced hyperlipidemia: a retrospective cohort study.Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?Drug interactions with sunitinib.Management of adrenal cancer: a 2013 update.Cushing's syndrome: an update on current pharmacotherapy and future directions.Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome.CYP3A activity: towards dose adaptation to the individual.Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.Everolimus therapy for progressive adrenocortical cancer.Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.Adrenocortical carcinoma Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art A fly in the ointment: reassessing mitotane’s role in the treatment of adrenocortical carcinoma

P2860

Q26801839-E26593B8-8B94-48F1-AE7E-B477880F01CA Q35018399-B5A2555C-3A86-4DF0-A712-A4410B22ABC3 Q35916555-FF4848E0-CB0C-42CD-81FA-FD8E57317BAA Q36928036-572C88D0-DD50-4E5A-B17D-64B225B73FE7 Q37119581-F5796CAB-15C2-4F76-BC49-4DECCE814E6B Q37358489-B6062DE5-0567-4B37-89DA-692C01B5DA5F Q37502558-F384BA00-8FAA-4289-8936-FC1F0B176037 Q37967559-368D57AB-B2CB-4A6B-B7C7-7C2D3B94A28D Q38176853-D2018AED-D9B5-48C0-B95A-FA033573759A Q38181425-44FD347C-493F-4D1D-A74C-0EC0D1123F4D Q38541695-C84878FD-A7FE-4E5F-A1FA-0B3359C50402 Q38545507-89A380B4-C975-48D4-A1AA-D35C1AE34E1E Q38713191-284DA8EA-64B9-4C88-87CE-B138EFB7669A Q38718807-6662EC8F-76E0-4BFF-BD89-E6A7BB9EF4F9 Q38763583-78215EC8-B777-4DF5-B589-AB9BF3F85C77 Q38925278-C1544E17-8EB7-446E-A304-54A25AFC55ED Q40862337-5C539879-5DB5-4827-91FD-D7DE50990C50 Q43478917-7A1BF128-89CD-4B7B-9F5F-3FABDF7CAF07 Q47957959-108A8ED7-9049-4282-82F2-BEAD745992DB Q51210622-95711BFB-76FC-493B-85E2-24765D4E3438 Q51504147-25470BC1-5056-4C1C-808C-A570E555F000 Q53251508-AD34A2D3-E285-49D3-9408-6DC403F6BDFF Q57645859-D8DFCFA6-872A-43FE-A7B1-B34050522C51 Q57822726-217BD003-1935-4864-9657-B3AB7F8E9858 Q58049948-F420EFAB-6D37-4E4D-87E2-6B6547C44A89

P2860

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

http://www.wikidata.org/entity/Q37924869

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Drug interactions with mitotan ...... t of adrenocortical carcinoma.

@en

Drug interactions with mitotan ...... t of adrenocortical carcinoma.

@nl

type

label

Drug interactions with mitotan ...... t of adrenocortical carcinoma.

@en

Drug interactions with mitotan ...... t of adrenocortical carcinoma.

@nl

prefLabel

Drug interactions with mitotan ...... t of adrenocortical carcinoma.

@en

Drug interactions with mitotan ...... t of adrenocortical carcinoma.

@nl

P1433

Q37924869-5C06295F-07FC-4935-A18C-CAB0A99B3E0F

P1476

Q37924869-71A4C7D7-5F4A-4EF1-B157-85368501AB0E

P2093

Q37924869-889ECEB5-01AB-4906-BBAE-A7B3681BBFBE

Q37924869-B6BC6CCC-2310-4103-ACB4-ED902B2E8CD2

Q37924869-CE429522-801C-46BA-AC35-BFE2A37FF4F4

Q37924869-D319AD11-07CC-43A3-9D7E-D7BA78B763AF

P2860

Q37924869-041807C3-92C2-4699-8422-EB3B9108601A

Q37924869-050141B6-D0A4-4EB2-AEC2-1C684BB01F9F

Q37924869-088002C0-4E6D-4214-B362-4C0D13D6CAA3

Q37924869-0BF99E03-569D-498E-8D28-0F5F29E8CB91

Q37924869-0F74C2FE-B580-4911-AD69-ABED69D379BB

Q37924869-1245BDC2-4237-4D1B-829B-E9126B205F5A

Q37924869-1524CF2E-7356-4530-B040-2938EE4B8BEE

Q37924869-18C9A6FF-A50D-4B47-829A-2D2F221AA979

Q37924869-24E20444-0777-4871-A0B4-AC0E63EEFB06

Q37924869-2EA557FA-7C8D-4912-A5B7-D8F2AD1B9F28

P304

Q37924869-5A6229E0-2B84-41B8-90DC-54D7898DD991

P31

Q37924869-38BAC57C-92A6-4044-B766-4C320E95019B

P356

Q37924869-892BBCBB-FE25-449A-9FCF-E7DDDCF3FCB8

P433

Q37924869-2C50EA2A-71A2-454D-AE93-87173BC4D523

P478

Q37924869-57910DA2-D08A-4B08-B84B-CE592862C0BE

P50

Q37924869-6A65E914-3EC6-4B2C-9F37-B454C1E6639F

P577

Q37924869-4BF3F7D0-B48F-4681-AD32-F18D0880AC39

P5875

Q37924869-CECDEFB4-3C11-4947-AF61-FD0F53D731D1

P698

Q37924869-1E1C8FED-A838-41DD-B946-FFBDE0F46667

P356

J.1365-2265.2011.04214.X

P1433

Clinical Endocrinology

P1476

Drug interactions with mitotan ...... t of adrenocortical carcinoma.

@en

P2093

Bruno Allolio

http://www.w3.org/2001/XMLSchema#string

Martin Fassnacht

http://www.w3.org/2001/XMLSchema#string

Matthias Kroiss

http://www.w3.org/2001/XMLSchema#string

Werner K Lutz

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone

Adjuvant mitotane treatment for adrenocortical carcinoma

Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas

Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.

Drug interactions with the taxanes: clinical implications.

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Metabolism considerations for kinase inhibitors in cancer treatment

Cytochromes P450 and metabolism of xenobiotics.

P304

585-591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2265.2011.04214.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Marcus Quinkler

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51610314

http://www.w3.org/2001/XMLSchema#string

P698

21883349

http://www.w3.org/2001/XMLSchema#string